Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2011

View Archived Issues

Phase II data reveal antitumor activity of SCH-727965 in breast cancer but not in NSCLC

Pfizer and UCSD describe PF-04449913, an oncolytic agent now in phase I development

AstraZeneca reports potent antidepressant/anxiolytic effects for AZD-2327 in vivo

GenKyoTex patents novel NADPH oxidase inhibitors

Cancer vaccines with tumor antigen H/K-HELP induce Th1 immune responses in patients

Small-molecule erythropoietin mimetic STS-E15 displays neuroprotective activity in vitro

Anavex begins dosing in phase I trial of ANAVEX 2-73 for Alzheimer's disease

Stanford University and SanBio begin phase I/II trial of cell therapy SB6-23 for stroke disability

New PRL-R-directed antibody LFA-102 shows promise as an oncolytic in preclinical tests

Qilu Pharma presents new receptor tyrosine-protein kinase inhibitors

Takeda claims novel ionotropic glutamate receptor agonists

New HSP 90 inhibitors synthesized by Aegera scientists

Chinese researchers prepare novel antibacterial and antifungal agents

Boston Scientific announces U.S. approval and launch of Ion paclitaxel-eluting stent

AIC-246 receives European orphan drug status for prevention of HCMV disease

Kyowa Hakko Kirin files NDA in Japan for KW-0761 in adult T-cell leukemia-lymphoma

Merck & Co. and Sanofi Pasteur begin phase III program for pediatric hexavalent combination vaccine

Mochida receives marketing approval in Japan for antidepressant Lexapro 10 mg

Tissue Genesis begins phase I/II trial of ASC-coated vascular grafts in peripheral vascular disease

European Commission approves Hizentra for primary and secondary immunodeficiencies

Kuros' phase IIb trial of KUR-113 in open tibial shaft fractures meets primary endpoint

Thymoglobuline is approved in Japan for treatment of acute renal transplant rejection

Japanese approval for Tramcet tablets for noncancer pain and pain after tooth extraction

Idera Pharma delays phase II study of IMO-2125 pending further toxicology results

Noscira begins phase IIb European trial of Nypta in Alzheimer's disease

Dosing begins in phase IIb study of TB-402 to prevent venous thromboembolism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...